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Dear Dr. Soede,
First of all, I would like to congratulate you for pro-
ducing this excellent special issue of Technology and
Disability on outcome assessment of assistive technol-
ogy. It is a good example of bringing together the vari-
ous disciplines involved in the very difficult discipline
of the assessment of assistive technologies. Although
your special issue encompasses a variety of relevant
issues I would like to give a short reaction, with my
own reference as neural prostheses (although not en-
tirely comparable with AT) as a starting point. My
comments are intended to contribute to the discussion
you started. You have acknowledged the important is-
sue of increased consumerism and presented different
contributions that each address one piece of the puzzle.
I would like to make some remarks regarding shared
decision-making with consumer involvement as well as
the role of economic evaluation of assistive technolo-
gies.
The consumer perspective: Consequences for
decision-making regarding assistive technologies
In the first few sentences of the editorial by Dr.
Gelderblom and Dr. De Witte it was stated that the as-
sessment of outcome of assistive technology has been
given more and more attention due to increased con-
sumerism and concerns about the quality of assistive
technology in relation to costs. Next, both authors write
that the objective of the special issue is to present a set
of instruments that can be used to study the effects or
costs of AT delivery. Although this is somewhat con-
fusing I assumed that it is not the purpose to address the
process of AT delivery itself, including legislative and
organisational barriers to overcome. Instead, I assumed
that we are concerned with an appropriate (technical)
prescription of the AT to an individual patient or client.
Last year, a paper was published in medical deci-
sion making that concludes that communication be-
tween physicians and patients needs to be enhanced.
They performed an experiment in which they asked pa-
tients and their physicians to rate the health-state of the
patients immediately after seeing the physician using
SF12 and standard gamble. A lack of congruence was
found in the ratings of patients’ health status by patients
and their physicians [4]. More recently, a paper pub-
lished by Gurmankin et al. showed that physicians are
able to dominantly influence patients in their decisions.
They offered different hypothetical treatment scenarios
in which the choice that maximises health was obvious
and across these scenarios they varied physicians’ rec-
ommendations in three ways, i.e. support of best treat-
ment scenario, against best scenario and no recommen-
dation. They conclude that physicians can influence
patients to take decisions that even go against the best
option [1].
Given these publications, it can be concluded that an
appropriate prescription of assistive technology to an
individual patient should be perfectly balanced with the
intended users. I appreciate the involvement of the con-
sumer in general and in your special issue in particular.
However, you addressed many different aspects (QoL,
individual goals, social participation, etc.) and an over-
all approach is lacking. The Life-H instrument, the
psycho-social impact (PIADS), Quest and to a lesser
extend the IPPA, all aim to assess the impact that the
AT may have in daily life and whether the AT has met
the individual goals.
The first point in this respect is that most instruments
are designed to measure retrospectively, and in order to
facilitate appropriate decision-making,I would be more
concerned with determinants of the effects and aban-
donment of AT. The only instrument that addresses the
users’ predisposition is the MPT instrument. However,
the MPT is designed as a generic measure and I am not
sure if these instruments are able to support decision-
making within a same category of ATs (e.g. walking
sticks). Although the role of consumers does actually
become more important in decision-making, my com-
ment related to your special issue is that you have pre-
dominantly focussed on the influence of the consumer
aspect, e.g. does the AT meet the expectations, satisfac-
tion with AT, quality of social participation. First and
foremost, I think that the rehabilitation professionals
can play a very important role by providing informa-
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tion and to reflect whether patient goals are realistic.
This required interaction is not really addressed, and I
would like to suggest to learn from other disciplines in
which they work on shared decision-making programs.
The other question is what other role (beside the
role in decision-making) the consumer could have. In
countries with a controlled health care insurance it is
obvious that there is some mechanism to control which
technologies to include in the benefit package. In health
economics it is often argued that societal values should
be used to decide about health gain, i.e. society has to
pay the insurance premium. Background is the reality
that health care budgets are still rising, and choices
have to be made given the budget limitations. My
impression is that in the current special issue, clients
and consumers are primarily responsible for judging
their own health gain. Although I can understand this
from a user’s point of view, it is not the line of thinking
in health economics.
In other words, consumer involvement is important
in decision-making but the present contributions in the
special issue only marginally address the interaction
between different stakeholders in the decision-making
process. Secondly, there should be more thought on the
role of the consumer in relation to valuing health gain
and negotiations about the benefit package and actual
payment of ATs.
In our institute we are elaborating on different ap-
proaches to include consumer opinions in health care
decision-making. Conjoint analysis is a technique in
which hypothetical treatment scenarios are designed
and offered pair-wise to respondents. They have to
choose which one they prefer and this choice-based
technique (compared to user satisfaction surveys) ba-
sically approaches real-life where decisions have to be
made every day. Also, we are preparing to use the
Analytic Hierarchy Process (AHP) as a means of deci-
sion making. The AHP is a quantitative technique to
analyse decisions that are impacted by multiple quan-
titative and even qualitative factors. This technique is
very powerful, also for individual decision-making, be-
cause it can include professional, consumer and payer
perspectives.
Economic evaluation of assistive technology
As far as I could understand from the editorial it is the
objective to focus on cost and effectiveness. An excel-
lent contribution was provided by Dr. Andrich about the
individual cost-scenarios of AT. Two minor comments
which I would like to make, are the perspective for eco-
nomical data collection and again the prediction of the
appropriateness of a prescription. In his contribution
Dr. Andrich has chosen the perspective of the clinician,
whereas most economic analyses are conducted from
the societal perspective. Like many others, we found
that cost-containment is an issue of interest for insur-
ance companies but only marginally for clinicians [2].
Also, the last ISTAHC conference in Berlin again ad-
dressed the lack of using of cost-effectiveness results
for health care decision-making. I doubt if clinicians
do really use this instrument to support their decisions,
because there are no incentives to do so.
The editorial started with the conclusion that there
are concerns about quality in relation to costs. In the
present special issue the outcome and cost components
of an economic evaluation were addressed separately,
but none intended to combine them into a single ratio.
One very important cost-driver is abandonment of the
AT. As far as we could judge, the abandonment was not
included in the SCAI instrument. Neither was client
time (needed to prepare or use AT) valued. The latter
seems very important to me regarding AT. During last
year’s IFESS conference in Cleveland a special session
was organised by Kevin Kilgore and Marcia Scherer
about consumer priorities for research directions. One
of the conclusions was that participants want to regain
independence and the ability to participate in activities
without a lot of preplanning and preparation [3]. This
observation is very challenging to anticipate regarding
the actual use and economic evaluation of AT.
Finally, one remark about the international perspec-
tive. I assume that, like in multi-national economic
evaluations, there are many differences between coun-
tries regarding the health insurance system. Whereas
a consumer-oriented approach may be very applicable
in the US, it is more difficult in countries that have a
more centrally controlled health care insurance system.
In the latter, judgements are made regarding inclusion
of technologies in the benefits package. Even within
Europe, there are major differences between countries
with respect to the use of outcome measures. The Euro-
pean project ACROSS (Across Cultures Rehabilitation
Outcomes StudieS) addressed this on a European scale
regarding functional disability scales. Although inter-
national collaboration is essential to learn from each
other, we also should anticipate the differences between
countries.
Yours sincerely,
Maarten J. IJzerman, PhD, PT
Scientific Director
Roessingh Research and Development
The Netherlands
Jaap de Vries, MD, PhD
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